In 2017, this seminal study proved that targeting inflammation reduces the risk for secondary cardiovascular events in patients, but US Food and Drug Administration approval for the use of IL-1β humanized neutralizing antibody canakinumab was not granted because the data were considered insufficient to justify routine use in patients with ASCVD. This evidence concerns the gene IL1B and atherosclerosis.